Aortic Stiffness Can be Predicted From Different eGFR Formulas With Long Follow-Up in the Malmö Diet Cancer Study

Abstract

We studied the impact of estimated glomerular filtration rate (eGFR) based on either creatinine or cystatin C, or in combination, on vascular aging (aortic stiffness) and central hemodynamics (central systolic blood pressure) in a Swedish urban population with median 17 years of follow-up. Participants (n = 5049) from the population-based Malmö Diet and Cancer Study that underwent baseline examination and later participated in the prospective cardiovascular arm were selected. Of these, 2064 with measured carotid-femoral pulse wave velocity (cfPWV) and central blood pressure at follow-up were enrolled. eGFR was calculated using cystatin C (eGFR_CYS) and creatinine (eGFR_CR) equations: Caucasian, Asian, pediatric, and adult cohorts (CAPA), the Lund-Malmö revised (LMrev), and the European Kidney Function Consortium (EKFC) equations. Lower adjusted eGFR_CR, but not eGFR_CYS, were independently associated with higher cfPWV (P < .001, respectively). eGFR <60 mL/min/1.73 m² determined higher cfPWV except when using the EKFC equation. Conversely, CAPA/LMrev and CAPA/EKFC ratios were not associated with aortic stiffness. Lower eGFR_CR is associated with higher future aortic stiffness independently of age, sex, heart rate, mean blood pressure, body mass index, and antihypertensive treatment. The ratio of eGFR_CYS and eGFR_CR equations could not predict aortic stiffness at all.

Keywords

aortic stiffness kidney function cystatin C epidemiology estimated glomerular filtration rate

Introduction

Vascular aging has become an important research topic in recent decades since it may reflect our biological age and play an essential role in predicting cardiovascular risk^1,2 and all-cause mortality.² In some conditions chronological age does not correspond with biological age, for example, in chronic kidney disease (CKD). The bidirectional pathophysiologic mechanisms between the cardiovascular and renal systems are associated with accelerated arterial stiffening in CKD.^3–5 Considering that arterial stiffness proceeds hypertension,⁶ targeting it during its early stages seems to be important to reduce cardiovascular risk, spare cognitive function,^7,8 and prevent kidney function decline.⁹

CKD represents a wide variety of vascular remodeling, including atherosclerosis, arteriosclerosis (or arterial stiffness), tunica intima and media calcification, and microcirculatory rarefaction.^10–13 It remains uncertain whether aortic stiffness causes kidney function loss or the opposite—changes in kidney microcirculation and, consequently, increased peripheral resistance resulting in increased stiffness.¹⁰ This report aims to address aortic stiffness as an outcome related to baseline kidney function (estimated glomerular filtration rate, eGFR). We also address the issue of inconsistent results when comparing cystatin C-based eGFR with creatinine-based eGFR, recently defined as selective glomerular hyperfiltration syndrome or shrunken pore syndrome,¹⁴ and its association with future aortic stiffness.

With this background, we hypothesize that lower baseline eGFR based on cystatin C, or a combination of creatinine and cystatin C, predicts aortic stiffness, measured as carotid-femoral pulse wave velocity (cfPWV), after a mean 17 years of follow-up in a Swedish urban population.

Materials and Methods

Study Design and Participants

During 1991–1996, the population-based prospective Malmö Diet and Cancer Study (MDCS)^15,16 recruited residents of Malmö city in Sweden: 17 035 women (with a primary goal to analyze incident breast cancer) and 11 063 men (with a primary goal to explore incident prostate cancer), born 1923–1950 and 1923–1945, respectively.

Between 2007 and 2012, some of these individuals (n = 6103) were randomly re-examined in the cardiovascular arm (MDCS‐CC).¹⁷ Out of 6103 participants at baseline (1994–1996), in all 2685 had both creatinine and cystatin C measured at baseline, as well as cfPWV measurements at the re-examination (2007–2012). This corresponds to a follow-up of 17 years (IQR 2.37, range 16–21 years). A total of 621 were octogenarians at the follow-up and therefore excluded from the study (see the flow chart in Figure 1).

Figure 1.

Flow chart of study participants. Abbreviations: MDCS, Malmo Diet Cancer study; MDCS-CC, Malmo Diet Cancer study cardiovascular cohort.

Measurements

Demographics

Diabetes mellitus was determined at baseline by a fasting blood glucose level ≥6.1 mmol/L, self-reported diabetes diagnosis, register-based prevalent diabetes diagnoses if available, or use of antidiabetic treatment. Hypertension was defined at baseline examination as use of antihypertensives, a previous diagnosis of hypertension, or a systolic blood pressure (SBP) ≥140 mmHg, and a diastolic blood pressure (DBP) ≥90 mmHg.

SBP and DBP at baseline were measured manually on the right overarm by trained nurses using a mercury-column sphygmomanometer twice in the supine position after 10 min of rest. Average blood pressure from two readings was computed. Mean arterial pressure (MAP) was calculated using the formula SBP+2DBP/3 (mmHg).

Biochemistry at Baseline

Fasting blood samples were collected and then frozen (−80°C) in a biobank. Following kidney function biomarkers were measured: plasma creatinine (μmol/L) (Jaffé method)¹⁸; plasma cystatin C (mg/L) (particle-enhanced immunonephelometric assay [N Latex Cystatin; Dade Behring, Deerfield, IL, USA]).¹⁹ Since cystatin C was analyzed before 2010 when the worldwide calibrator was introduced, we had to standardize the values by using methods as described previously.²⁰

Central Hemodynamic and Measurement of cfPWV at Follow-Up

Central systolic blood pressure (cSBP) and the cfPWV were examined after a mean follow-up of 17 years (IQR 2.34) by using the applanation tonometry (SphygmoCor, AtCOR Medical, Sydney, Australia) that utilizes the foot-to-foot method to define the transit time through intersecting tangents algorithm. The heart rate was monitored using simple three-lead electrocardiography. Peripheral blood pressure (pSBP and pDBP) was measured after 10 min of supine rest with an automatic device (OMRON M5-1 IntelliSense, Kyoto, Japan).

First, the pulse wave was recorded on the pulse site of the carotid artery, and then on the pulse site of the femoral artery, simultaneous ECG registration was performed. Finally, the distance was measured by using a tape from the measuring point on the carotid artery (CA)—to the suprasternal notch (SSN)—then to the umbilicus (UMB)—and finally to the measuring point at the femoral artery (FA) site minus the suprasternal notch to the measuring point at the carotid artery:

Distance = (SSN - UMB - FA) - (SSN - CA)

Three cfPWV measurements were performed for each individual, and the average cfPWV value was calculated.

Since the CA-FA distance multiplied by 0.8 has the best agreement with real traveled aortic path length measured by using magnetic resonance imaging,²¹ we applied a conversion factor to calculate standardized values of cfPWV in our population:

cfPWV = {cfPWV}_{measured} \times 1.083

A conversion factor “1.083” is based on MRI refrence values for pulse travel distance validated by Huybrechts et al.²¹

Estimation of Kidney Function at Baseline

Kidney function was determined by using creatinine and cystatin C-based eGFR formulas: cystatin C eGFR equation based on Caucasian, Asian, pediatric, and adult cohorts (CAPA)²²; the Lund-Malmö revised creatinine-based eGFR equation (LMrev)²³; and the European Kidney Function Consortium (EKFC) equation for creatinine.²⁴ LMrev equation has been validated in a Swedish population²⁵ and is superior to other creatinine-based equations, such as the Modification of Diet in Renal Disease (MDRD) study and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).

To account for different cystatin C and creatinine filtration, previously described by Grubb²⁶ and recently named selective glomerular hypofiltration syndromes,¹⁴ we calculated the ratio between CAPA and LMrev, and CAPA and EKFC.

Statistical Analysis

For continuous variables, mean and standard deviations (SDs) were used; for discrete variables, medians with interquartile ratio (IQR) were used; and for categorical variables, numbers and percentages were used. Before deciding which test to use (mean comparison or nonparametric), F-test was performed to test the equality of two populations for normally distributed continuous data. For not normally distributed data, nonparametric tests were applied. Spearman´s correlation test was carried out to define the correlations among variables if at least one was not normally distributed. Adjusted P-values (Holm–Bonferroni method) were used to counteract the problem of multiple comparisons. eGFR was analyzed both as a continuous variable and as a categorical variable. We divided eGFR into groups: eGFR below <60, 60–90, and >90 mL/min/1.73 m.²

A generalized linear regression model (univariate and multivariate) was used for analyzing the relationship between eGFR (independent variable) and aortic stiffness (c-fPWV; dependent variable). We put all significant factors from univariate analysis into one multivariable model. After stepwise model selection adjustment for confounders such as age, sex, MAP, heart rate (HR), body mass index (BMI), and antihypertensive treatment available for 819 participants, creatinine-based eGFR remained relevant in predicting cfPWV. We used variation inflation factor (VIF) to address multicollinearity; variables excluded when sqrtVIF >2. The association between aortic stiffness and discrepancy in cystatin C/creatinine eGFR ratio was also analyzed.

Rcrmdr version R 3.6.2 GUI 1.70 El Capitan build macOS (McMaster University, Hamilton, Ontario, Canada) was used for statistical analysis. The significance level was defined by two-sided P < .05.

Results

General Characteristics of the Study Population

The general demographic characteristics are highlighted in Table 1. The data on excluded individuals is presented in Supplemental Table 1.

Table 1.

Demographic and Clinical Characteristics of Study Subjects. Means (SD) or proportions.

Variable	Total (n = 2064)	Women (n = 1286)	Men (n = 778)
Baseline characteristics
Age, at baseline, years	53 (4)	53 (4)	53 (4)
Diabetes, yes	27 (1.6)	15 (2.3)	12 (1.2)
Hypertension, yes	558 (27.0)	241 (31.0)	317 (24.7)
Smoking status†:
- Current	393 (19.4)	241 (19.0)	152 (20.0)
- Former	807 (39.8)	364 (28.7)	443 (48.2)
BMI, kg/m²	25.1 (3.5)	24.7 (3.7)	25.7 (3.2)
pSBP, mmHg	136 (17)	135 (17)	139 (17)
pDBP, mmHg	86 (9)	84 (9)	88 (9)
MAP, mmHg	103 (11)	101 (11)	104 (11)
Cystatin C, mg/L	1.11 (0.21)	1.12 (0.22)	1.10 (0.19)
Creatinine, µmol/L	83 (14)	78 (12)	91 (14)
CAPA, mL/min/1.73 m²	68 (15)	68 (15)	69 (14)
LMrev, mL/min/1.73 m²	80 (12)	85 (11)	74 (10)
EKFC, mL/min/1.73 m²	77 (13)	74 (12)	82 (11)
eGFR_CAPA-LMrev, mL/min/1.73 m²	74 (11)	76 (11)	71 (10)
eGFR_CAPA-EKFC mL/min/1.73 m²	73 (12)	76 (11)	71 (11)
Follow-up measurements
Age, at follow-up, years	70 (4)	70 (4)	71 (4)
Smoking status†:
- Current	151 (7.3)	93 (7.2)	58 (7.5)
- Former	979 (47.4)	552 (42.9)	427 (54.9)
Lipid-lowering treatment†, at follow-up, yes	31 (3.8)	17 (7.9)	14 (2.3)
Anti-HT treatment‡, at follow-up, yes	223 (27.2)	85 (22.8)	138 (22.8)
cfPWV, m/s	10.95 (2.45)	10.74 (2.26)	11.29 (2.70)
HR, bpm	67 (11)	68 (10)	65 (11)
pSBP, mmHg	134 (17)	134 (17)	135 (16)
pDBP, mmHg	76 (9)	75 (9)	77 (9)
cSBP, mmHg	121 (17)	121 (17)	121 (15)
cDBP, mmHg	75 (9 (	74 (9)	76 (9)
cPP, mmHg	47 (12)	47 (12)	45 (10)
MAP, mmHg	103 (11)	101 (11)	104 (11)

Data expressed as mean (± SD/IQR) or number (%).

Data available † for 1269 women and 761 men; ‡ for 604 women and 215 men.

Abbreviations: Anti-HT, antihypertensive treatment; WC, waist circumference; WHR, waist-to-hip ratio; pSBP, peripheral systolic blood pressure; pDBP, peripheral diastolic blood pressure; cSBP, central systolic blood pressure; cDBP, central diastolic blood pressure; MAP, mean arterial pressure; cPP, central pulse pressure; HR, heart rate; cfPWV, carotid-femoral pulse wave velocity; CAPA, cystatin C eGFR equation based on Caucasian, Asian, pediatric, and adult cohorts; LMrev, the Lund-Malmö revised creatinine-based eGFR equation; EKFC, European Kidney Function Consortium equation; eGFR_CAPA-LMrev, average eGFR calculated from CAPA and LMrev; eGFR_CAPA-EKFC, average eGFR calculated from CAPA and EKFC.

Kidney Function and Arterial Stiffness

Kidney function at the inclusion to the study, calculated by five eGFR equations, is visualized in Figure 2. Figure 3 depicts how diverse eGFR equations classify kidney function among individuals studied.

Figure 2.

Distribution of baseline estimated glomerular filtration rate in the study subjects. Abbreviations: CAPA, cystatin C eGFR equation based on Caucasian, Asian, pediatric, and adult cohorts; LMrev, the Lund-Malmö revised creatinine-based eGFR equation; EKFC, European Kidney Function Consortium equation; CAPA-LMrev, average eGFR calculated from CAPA and LMrev; CAPA-EKFC, average eGFR calculated from CAPA and EKFC.

Figure 3.

Classification of kidney function by different equations. Abbreviations: CAPA, cystatin C eGFR equation based on Caucasian, Asian, pediatric, and adult cohorts; LMrev, the Lund-Malmö revised creatinine-based eGFR equation; EKFC, European Kidney Function Consortium equation; CAPA-LMrev, average eGFR calculated from CAPA and LMrev; CAPA-EKFC, average eGFR calculated from CAPA and EKFC.

We observed that lower baseline eGFR is associated with higher predicted cfPWV at follow-up (Table 2). Only creatinine-based equations performed well in identifying this relationship. Additionally, creatinine-based EKFC equation showed a very weak association with central systolic blood pressure (Table 2) that disappeared after multiple adjustments.

Table 2.

Association Between Kidney Function and Carotid-Femoral Pulse Wave Velocity as Well as Central Systolic Blood Pressure.

Dependent variable	Ln (cfPWV)			cSBP
	Univariate			Univariate
	ß	95% CI	P	ß	95% CI	P
Age, years	0.016	0.01–0.02	<0.001	1.00	1.00–1.01	<0.001
Δ Age, years	0.003	−0.00–0.01	0.287	−0.53	−1.00–(-)0.05	0.029
Sex, female	−0.04	−0.06–(-)0.03	<0.001	0.58	−0.89–2.06	0.440
Diabetes, yes	0.13	0.05–0.21	<0.001	0.32	−6.03–6.67	0.921
Hypertension, yes	0.08	0.06–0.10	<0.001	6.23	4.65–7.83	<0.001
Antihypertensives, yes	0.08	0.04–0.10	<0.001	5.45	2.89–8.01	<0.001
Lipid-lowering drugs, yes	−0.01	−0.08–0.07	0.856	5.13	−1.18–11.43	0.111
BMI, kg/m²	0.01	0.08e-1–0.01	<0.001	0.28	0.08–0.49	0.007
MAP, mmHg	0.01	0.06e-1–0.07e-1	<0.001	1.33	1.30–1.35	<0.001
HR, bpm	0.04e-1	0.04e-1–0.05e-1	<0.001	−0.01	−0.07–0.06	0.883
CAPA, mL/min/1.73 m²	−0.01e-1	−0.02e-1–(-)0.03e-2	0.003	−0.02	−0.07–0.03	0.335
LMrev, mL/min/1.73 m²	−0.02e-1	−0.01e-1–(-)0.03e-1	<0.001	−0.04	−0.10–0.02	0.243
EKFC, mL/min/1.73 m²	−0.01e-1	−0.02e-1–(-)0.03e-2	0.010	−0.10	−0.12–(-)0.01	0.024
eGFR_CAPA-LMrev, mL/min/1.73 m²	−0.02e-1	−0.01e-1–(-)0.03e-1	<0.001	−0.04	−0.10–0.02	0.217
eGFR_CAPA-EKFC, mL/min/1.73 m²	−0.01e-1	−0.02e-1–(-)0.01e-1	<0.001	−0.06	−0.12–0.01	0.074

Generalized linear regression (identity link) model with logarithmed cfPWV and central systolic blood pressure (cSBP) as dependent variables.

Abbreviations: Δ Age, difference between age at follow-up and at the baseline; BMI, body mass index; HR, heart rate; MAP, mean arterial pressure; CAPA, cystatin C eGFR equation based on Caucasian, Asian, pediatric, and adult cohorts; LMrev, the Lund-Malmö revised creatinine-based eGFR equation; EKFC, European Kidney Function Consortium equation; eGFR_CAPA-LMrev, average eGFR calculated from CAPA and LMrev; eGFR_CAPA-EKFC, average eGFR calculated from CAPA and EKFC.

After stepwise model selection, LMrev and EKFC equations adjusted for age, sex, MAP, heart rate, antihypertensive medications, and body mass index showed the strongest significant relationship with cfPWV (Table 3). Neither Cystatin C nor eGFR average eGFR from a combination of cystatin C and creatinine were predictors of cfPWV.

Table 3.

Stepwise Model Selection of Variables Independently Associated With Carotid-Femoral Pulse Wave Velocity.

Dependent variable	Ln (cfPWV)
	Multivariate
	R ²	Mean Square	P
Model 1	0.209	1.219	<0.001
Model 2	0.216	1.050	<0.001
Model 3a	0.222	0.926	<0.001
Model 3b	0.227	0.944	<0.001

Stepwise linear model selection for 819 subjects that had data on use of antihypertensive treatment, ln(cfPWV) as dependent variable. Models with CAPA equation failed at predicting cfPWV.

Model 1: adjusted for age, sex, MAP, heart rate, and antihypertensive medication;

Model 2: Model 1 + BMI;

Model 3a: Model 2 + LMrev;

Model 3b: Model 2 + EKFC.

Abbreviations: ln(cfPWV), natural logarithm of carotid-femoral pulse wave velocity; BMI, body mass index; CAPA, cystatin C eGFR equation based on Caucasian, Asian, pediatric, and adult cohorts; LMrev, the Lund-Malmö revised creatinine-based eGFR equation; EKFC, European Kidney Function Consortium equation; MAP, mean arterial pressure.

Interestingly, when comparing cfPWV across eGFR categories (Figure 4), unlike the remaining four equations, the EKFC equation did not identify the variation of cfPWV (P = .102) among different eGFR levels. Of note, there were only 28 individuals classified as eGFR <60 mL/min/1.73 m² according to the CAPA-EKFC equation.

Figure 4.

Carotid-femoral pulse wave velocity in categories of kidney function. Abbreviations: eGFR, estimated glomerular filtration rate; eGFR categories, estimated glomerular filtration rate divided into groups: below 60 mL/min/1.73 m², between 60 and 90 mL/min/1.73 m², and above 90 mL/min/1.73 m²; CAPA, cystatin C eGFR equation based on Caucasian, Asian, pediatric, and adult cohorts; LMrev, the Lund-Malmö revised creatinine-based eGFR equation; EKFC, European Kidney Function Consortium equation; CAPA-LMrev, average eGFR calculated from CAPA and LMrev; CAPA-EKFC, average eGFR calculated from CAPA and EKFC; cfPWV, standardized carotid-femoral pulse wave velocity values. *P <0.05; **P < .001.

Additionally, neither the ratio of CAPA/LMrev nor CAPA/EKFC was related to aortic stiffness in the whole cohort (Supplemental Figure 1).

Discussion

Based on our observational findings, creatinine-based eGFR equations for renal function can predict aortic stiffness measured after a mean of 17 years in an urban, middle-aged Swedish population. Lower kidney function is thus independently associated with higher aortic stiffness in the future. This relationship is independent of age, sex, BMI, mean blood pressure, heart rate, and antihypertensive treatment. However, central blood pressure seems to be affected by factors other than historical kidney function. The discrepancy between cystatin C and creatinine-based equations was not associated with arterial stiffness in the whole cohort, suggesting different pathophysiological mechanisms responsible for large artery vascular aging and kidney aging.

Increased PWV, a marker of arterial stiffness, is one of the essential characteristics of vascular aging, reflecting arteriosclerosis.¹³ This study found that the lower the baseline creatinine-based eGFR, the higher cfPWV after a mean of 17 years of follow-up. This is the first report trying to link baseline kidney function to future aortic stiffness after such a long observational period in a population-based cohort. Previously published data from populations of comparable age and sex reported that in 482 individuals participating in the Maine Syracuse Longitudinal Study (MSLS),²⁶ kidney function decline over 4–5 years was associated with increased cfPWV. In contrast, a study based on HIPPOCRATES (Hypertension: Interaction and Prevalence of POlymorphisms related to Cardiovascular Risk and the Association to Treatment Efficacy Study) cohort²⁷ reported that in 222 subjects the baseline eGFR (CKD-EPI based on creatinine) could not predict annual cfPWV change during a follow-up of 5.6 years. These authors used creatinine-based equations: MDRD and CKD-EPI. We used eGFR equations, for example, LMrev, that are validated and adapted to the Swedish population.^23,25 Furthermore, combining eGFR formulas from creatinine and cystatin C values—that is, calculating the average eGFR—helps to achieve more precise kidney function assessment. ²⁸

Almost a decade ago, our colleagues²⁹ published a paper analyzing non-hemodynamical determinants of arterial stiffness in the same cohort. They found that cross-sectionally eGFR—calculated using CKD-EPI, based on both cystatin C and creatinine (adjusted for age, MAP, and heart rate)—was associated with cfPWV. However, the significance disappeared after additional adjustments for BMI, current smoking, and medication. The main issues with this first report are noncalibrated cystatin C values that underestimated kidney function, adjusting for lipid-lowering drugs unrelated to cfPWV according to univariate analysis, and not considering different time periods between measurements in individuals. In our analysis, we could address all these previous pitfalls and reveal the previously unidentified relationship.

Some of the research up till now has observed a cross-sectional link between cystatin C and PWV^30–32 or atherosclerosis³³ in patients with no or mild CKD, yet lacking data on follow-up. Though cystatin C gene variant rs13038305 failed to show any causal relationship with cardiovascular disease and mortality,^34,35 we believe that altered kidney filtration for cystatin C might be the key player in cardiovascular remodeling. The relation between heart and kidney, represented by the cardiorenal syndrome, may be caused by common vascular changes giving rise to different elimination patterns for small- and middle-sized molecules described in the so-called selective glomerular hypofiltration syndromes¹⁴ represented by a cystatin C/creatinine-based eGFR ratio <0.7. Observed clearance changes of molecules with different molecular masses have been associated with an accumulation of middle-sized atherosclerosis-promoting proteins, but not with small molecules like creatinine.³⁶ We could not find an association between low cystatin C/creatinine-based eGFR ratio and future cfPWV that could be similar to previously reported relationship with the cardiorenal syndrome.³⁷ One explanation is the lack of cross-sectional data and the limited knowledge about events that could have affected the course of vascular aging. The complex mechanism in micro- and macrovascular remodeling³⁸ inconsistent with those possibly related to selective hypofiltration may be the other reliable explanation for this lack of association. However, further studies should focus on how microvascular changes affect sieving for molecules with greater masses in kidneys and if they are related to renal resistance.³⁹

The strength of this study is standardizing of cfPWV on the actual aortic path length based on MRI studies, the prospective evaluation of aortic stiffness, and use of eGFR equations adapted to the studied population. Adding cystatin C analysis to routine creatinine analysis is a cost-effective method that improves the diagnosis of CKD and risk prediction.

The limitation is that we did not have interim measurements either of kidney function or aortic stiffness that could depict the time slope of these variables. In addition, during these 17 years, many other risk factors could have influenced kidney function, in particular chronological age. Therefore, octogenarians were excluded from the analysis. However, we assume that subjects who agreed to participate in the re-examination were likely not affected by a high disease burden (health selected) since these cardiovascular examinations were rather extensive and time-consuming.^17,40 Another limitation is that only office blood pressure (BP) was used at baseline screening and not 24-h ambulatory blood pressure measurement, a more precise measure of hemodynamic function and BP.

In summary, we identified that lower kidney function based on creatinine and cystatin C could predict future aortic stiffness in a middle-aged Swedish population, independent of mean arterial pressure. The phenomenon of lower eGFRcystatin C/eGFRcreatinine ratio could not be shown in this study. Further studies are warranted to analyze the relationship between selective hypofiltration syndromes and vascular aging, preferably in a cross-sectional manner.

Supplemental Material

Supplemental Material - Aortic Stiffness Can be Predicted From Different eGFR Formulas With Long Follow-Up in the Malmö Diet Cancer Study

Supplemental Material for Aortic Stiffness Can be Predicted From Different eGFR Formulas With Long Follow-Up in the Malmö Diet Cancer Study by Anders Christensson, MD, PhD, Simon Lundgren, MD, Madeleine Johansson, MD, PhD, Peter M. Nilsson, MD, PhD, Gunnar Engström, PhD, and Agne Laucyte-Cibulskiene, MD, PhD in Angiology.

Footnotes

Acknowledgments

On behalf of the European Kidney Function Consortium, the authors acknowledge the support of the European Renal Association (ERA), The Swedish Kidney Foundation, Fulbright Commission, Stiftelsen för njursjuka, Skåne University Hospital Research Fund, the Research and Development Council of Region Skåne, Sweden, and the Medical Faculty of Lund University in publishing study results. The authors are grateful for COST action VascAgeNet 18216 for inspiring further research in vascular aging.

Author Contributions

AC, PN, and AL developed hypothesis; AC and AL analyzed the data; AC, SL, and AL contributed in writing manuscript; AC, SL, MJ, PN, GE, and AL discussed the results and revised manuscript.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Swedish Cancer Foundation that has financially supported Malmö Diet and Cancer Study (MDCS), The Swedish Medical Research Council, The European Commission, the City of Malmö, the Swedish Dairy Association, and the Albert Påhlsson Foundation. The Malmö Diet Cancer Cardiovascular Arm Re-exam study was supported by the Research Council of Sweden and the Swedish Heart- and Lung Foundation with grants to Dr Peter M Nilsson. Dr Anders Christensson was supported by grants from the Medical Faculty of Lund University, the Swedish Kidney Foundation, Swedish Kidney Foundation, Skåne University Hospital Research Fund, and the Research and Development Council of Region Skåne, Sweden. Dr Agne Laucyte-Cibulskiene was supported by Swedish Research Council with ALF funding grant. Finally, the data management of MDCS was supported by the Lund University Infrastructure grant “Malmö population-based cohorts” (STYR 2019/2046).

Ethical Statement

ORCID iDs

Peter M. Nilsson

Agne Laucyte-Cibulskiene

Data Availability Statement

The datasets generated and/or analyzed during the current study, after deidentification (text, tables, figures, and appendices), could be extracted by sending application to MDC steering committee on reasonable request. Proposals should be directed to anders.dahlin@med.lu.se. To gain access, data requestors will need to sign a data access agreement.

Supplemental Material

Supplemental material for this article is available online.

References

Nilsson

. Early vascular aging in hypertension. Front Cardiovasc Med. 2020;7:6.

Vlachopoulos

Aznaouridis

Stefanadis

. Prediction of cardiovascular events and all-cause mortality with arterial stiffness. A systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318-1327.

Inserra

Forcada

Castellaro

. Chronic kidney disease and arterial stiffness: a two-way path. Front Med (Lausanne). 2021;8:765924.

Garnier

Briet

. Arterial stiffness and chronic kidney disease. Pulse. 2016;3:229-241.

London

. Arterial stiffness in chronic kidney disease and end-stage renal disease. Blood Purif. 2018;45:154-158.

. Arterial stiffness and hypertension. Clin. 2018;24:17.

Tsao

Himali

Beiser

, et al. Association of arterial stiffness with progression of subclinical brain and cognitive disease. Neurology. 2016;86:619-626.

Mitchell

van Buchem

Sigurdsson

, et al. Arterial stiffness, pressure and flow pulsatility and brain structure and function: the Age, Gene/Environment Susceptibility-Reykjavik Study. Brain. 2011;134:3398-3407.

Sedaghat

Mattace-Raso

FUS

Hoorn

, et al. Arterial stiffness and decline in kidney function. Clin J Am Soc Nephrol. 2015;10:2190-2197.

10.

Querfeld

Mak

Pries

. Microvascular disease in chronic kidney disease: the base of the iceberg in cardiovascular comorbidity. Clin Sci. 2020;134:1333-1356.

11.

Brandenburg

Schuh

Kramann

. Valvular calcification in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26(6):464-471.

12.

Düsing

Zietzer

Goody

, et al. Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches. J Mol Med (Berl). 2021;99:335-348.

13.

Mitchell

Powell

. Arteriosclerosis: a primer for ‘in focus’ reviews on arterial stiffness. Arterioscler Thromb Vasc Biol. 2020;40:1025-1027.

14.

Malmgren

Öberg

den Bakker

, et al. The complexity of kidney disease and diagnosing it - cystatin C, selective glomerular hypofiltration syndromes and proteome regulation. J Intern Med. 2023;293:293-308.

15.

Manjer

Carlsson

Elmståhl

, et al. The Malmö Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev. 2001;10:489-499.

16.

Hedblad

Nilsson

Janzon

Berglund

. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmö, Sweden. Diabet Med. 2000;17:299-307.

17.

Rosvall

Persson

Östling

, et al. Risk factors for the progression of carotid intima-media thickness over a 16-year follow-up period: the Malmö Diet and Cancer Study. Atherosclerosis. 2015;239:615-621.

18.

Delanghe

Speeckaert

. Creatinine determination according to Jaffe - what does it stand for? NDT Plus. 2011;4:83-86.

19.

Mussap

Ruzzante

Varagnolo

Plebani

. Quantitative automated particle-enhanced immunonephelometric assay for the routinary measurement of human cystatin C. Clin Chem Lab Med. 1998;36:859-865.

20.

Laucyte-Cibulskiene

Sharma

Christensson

Nilsson

. Early life factors in relation to albuminuria and estimated glomerular filtration rate based on cystatin C and creatinine in adults from a Swedish population-based cohort study. J Nephrol. 2021;35:889-900.

21.

Huybrechts

SAM

Devos

Vermeersch

, et al. Carotid to femoral pulse wave velocity: a comparison of real travelled aortic path lengths determined by MRI and superficial measurements. J Hypertens. 2011;29:1577-1582.

22.

Grubb

Horio

Hansson

, et al. Generation of a new cystatin C-based estimating equation for glomerular filtration rate by use of 7 assays standardized to the international calibrator. Clin Chem. 2014;60:974-986.

23.

Björk

Grubb

Sterner

Nyman

. Revised equations for estimating glomerular filtration rate based on the Lund-Malmö Study cohort. Scand J Clin Lab Invest. 2011;71:232-239.

24.

Pottel

Björk

Courbebaisse

, et al. Development and validation of a modified full age spectrum creatinine-based equation to estimate glomerular filtration rate : a cross-sectional analysis of pooled data. Ann Intern Med. 2021;174:183-191.

25.

Nyman

Grubb

Larsson

, et al. The revised Lund-Malmö GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population. Clin Chem Lab Med. 2014;52:815-824.

26.

Elias

Davey

Dore

Gillespie

Abhayaratna

Robbins

. Deterioration in renal function is associated with increased arterial stiffness. Am J Hypertens. 2014;27:207-214.

27.

van Varik

Vossen

Rennenberg

, et al. Arterial stiffness and decline of renal function in a primary care population. Hypertens Res. 2017;40:73-78.

28.

Björk

Grubb

Larsson

, et al. Accuracy of GFR estimating equations combining standardized cystatin C and creatinine assays: a cross-sectional study in Sweden. Clin Chem Lab Med. 2015;53:403-414.

29.

Gottsäter

Östling

Persson

Engström

Melander

Nilsson

. Non-hemodynamic predictors of arterial stiffness after 17 years of follow-up: the Malmö Diet and Cancer study. J Hypertens. 2015;33:957-965.

30.

Huang

Jiang

Wang

, et al. Serum cystatin C and arterial stiffness in middle-aged and elderly adults without chronic kidney disease: a population-based study. Med Sci Monit. 2019;25:9207-9215.

31.

Odaira

Tomiyama

Matsumoto

, et al. Association of serum cystatin C with pulse wave velocity, but not pressure wave reflection, in subjects with normal renal function or mild chronic kidney disease. Am J Hypertens. 2010;23:967-973.

32.

Ozkok

Akpinar

Tufan

, et al. Cystatin C is better than albuminuria as a predictor of pulse wave velocity in hypertensive patients. Clin Exp Hypertens. 2014;36:222-226.

33.

Král

Kovárník

Vaníčková

, et al. Cystatin C is associated with the extent and characteristics of coronary atherosclerosis in patients with preserved renal function. Folia Biol (Praha). 2016;62:225-234.

34.

O’Seaghdha

Tin

Yang

, et al. Association of a cystatin C gene variant with cystatin C levels, CKD, and risk of incident cardiovascular disease and mortality. Am J Kidney Dis. 2014;63:16-22.

35.

Svensson-Färbom

Almgren

Hedblad

, et al. Cystatin C is not causally related to coronary artery disease. PLoS One. 2015;10:e0129269.

36.

Almén

Björk

Nyman

, et al. Shrunken pore syndrome is associated with increased levels of atherosclerosis-promoting proteins. Kidney Int Rep. 2019;4:67-79.

37.

Christensson

Grubb

Molvin

, et al. The shrunken pore syndrome is associated with declined right ventricular systolic function in a heart failure population – the HARVEST study. Scand J Clin Lab Invest. 2016;76:568-574.

38.

Laurent

Agabiti-Rosei

Bruno

Rizzoni

. Microcirculation and macrocirculation in hypertension: a dangerous cross-link? Hypertension. 2022;79:479-490.

39.

Calabia

Torguet

Garcia

, et al. The relationship between renal resistive index, arterial stiffness, and atherosclerotic burden: the link between macrocirculation and microcirculation. J Clin Hypertens (Greenwich). 2014;16:186-191.

40.

Nilsson Wadström

Engström

Nilsson

. Exploring and comparing definitions of healthy vascular ageing in the population: characteristics and prospective cardiovascular risk. J Hum Hypertens. 2021;35:428-436.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.23 MB